Candel Therapeutics Shares Soar After FDA Fast Track of CAN-2409
By Dean Seal
Shares of Candel Therapeutics surged after U.S. federal regulators granted fast-track designation to its treatment for pancreatic ductal adenocarcinoma.
The stock was up 58% at $1.37 in premarket trading. Shares had fallen 51% year-to-date when the market closed Monday.
The clinical-stage biopharmaceutical company said Tuesday that the U.S. Food and Drug Administration granted the designation for CAN-2409, its lead investigational adenovirus asset, plus valacyclovir as a treatment to improve overall survival in patients with pancreatic ductal adenocarcinoma.
The FDA's fast-track designation facilitates development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 12, 2023 08:43 ET (13:43 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
What the Fed’s QT Program Is, and Why Its End Matters
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)